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Abstract: Programmed death-ligand 1 (PD-L1) expression is a predictor of immune checkpoint 
inhibitor (ICI) treatment efficacy. The clinical efficacy of PD-1 inhibitors for NSCLC patients 
harboring major mutations, such as EGFR or ALK, is limited. ALK gene rearrangement occurs 
in a small portion of patients with non-small cell lung cancer (NSCLC), but it accounts for 
about 30–40% of lung adenocarcinoma in young people and is present in many non-smokers. 
It has been reported that programmed death-ligand 1 (PD-L1) expression is high in 
ALK-positive lung cancer. PD-L1 expression is one of the predictors of efficacy for ICI 
treatment. However, there are few reports of studies that have investigated the efficacy of 
PD-1 inhibitors in ALK-rearranged NSCLC patients. Therefore, we compared the efficacies of 
ICIs for treatment of ALK-positive lung adenocarcinoma and other oncogene drivers, 
including EGFR mutations. We genotyped 190 advanced lung adenocarcinomas who 
received nivolumab or pembrolizumab monotherapy and examined the efficacy in NSCLC 
patients with or without major mutations. Forty-seven patients harbored the EGFR mutation, 
25 had KRAS, 5 had a HER2, 6 had a BRAF, and 7 had ALK rearrangement. The status of 
PD-L1 expression was evaluated in 151 patients, and the rate of high PD-L1 expression (≥50%) 
was significantly higher in patients with ALK mutations. The progression-free survival was 
0.6 (95% CI:0.2-2.1) months for ALK-positive patients and 1.8 (95% CI:1.2-2.1) months for 
EGFR-positive patients. All patients with ALK rearrangement showed disease progression 
within 3 months from the initiation of anti-PD-1 treatment. Our data suggested that ICI 
treatment was significantly less efficacious in patients with ALK rearrangement than in 
patients with EGFR mutations, and PD-L1 expression is not a critical biomarker for ICI 
treatment for patients with either mutations. 
	
